Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × PT2385 × Clear all

Phase

Status

Completed 2 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Kidney Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

pembrolizumab 393 Carboplatin 280 Cyclophosphamide 270 Nivolumab 268 Paclitaxel 225 Specimen Handling 224 Magnetic Resonance Spectroscopy 222 Cisplatin 219 Radiotherapy 199 Gemcitabine 164 Dexamethasone 164 durvalumab 160 Biopsy 156 atezolizumab 138 Lenalidomide 131 Doxorubicin 125 Bevacizumab 123 Rituximab 122 Ipilimumab 118 Docetaxel 118 Oxaliplatin 108 Capecitabine 108 Fluorouracil 106 Radiation 104 Radiosurgery 102 fludarabine 99 Etoposide 99 Pemetrexed 96 Prednisone 95 venetoclax 94

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02293980 2024-06-17

MK-3795-001

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡